UroToday is excited to bring you written conference highlights, written by uro-oncologists from the 2020 AUA Live Virtual Experience, June, 27-28 2020.
|
|
|
|
|
|
The American Urological Association Virtual Meeting
|
|
|
|
| 2020 AUA Live Virtual Experience |
| Ramon Guiteras Lecture: Active Surveillance for Low and Intermediate Prostate Cancer - the Past or the Future? |
| Peter Carroll, MD, MPH |
| The 2020 AUA virtual annual meeting’s Roman Guiteras Lecture was provided by Dr. Peter Carroll from UCSF, discussing active surveillance for low and intermediate risk prostate cancer. |
|
|
|
|
|
| AUA Guidelines 2020: Advanced Prostate Cancer |
| William T. Lowrance, MD, MPH and Michael Cookson, MD |
| The AUA 2020 virtual annual meeting was highlighted by an update on the AUA guidelines for advanced prostate cancer, presented by Dr. William Lowrance and Dr. Michael Cookson. Dr. Lowrance notes that this guideline was produced by a multidisciplinary panel with representation from the AUA, ASCO, ASTRO, and SUO was well as a patient advocate. Their systematic review was conducted from 1998 through January 20, 2020, and 192 publications were identified through an initial search, with an additional 46 carried over from the prior AUA CPRC review. |
|
|
|
|
|
| Coronavirus Infections: More Than Just the Common Cold |
| Anthony S. Fauci, MD |
| Anthony Fauci gave a presentation on the current worldwide pandemic caused by COVID-19, at the 2020 American Urological Association virtual experience. |
|
|
|
|
|
|
|
|
|
|
| Accuracy of 68Ga-PSMA-11 for Pelvic Nodal Metastasis Detection Prior To Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Study |
| Thomas Hope, MD |
| Thomas Hope presented a study aiming to determine the accuracy of 68Ga-PSMA-11 PET for the detection of pelvic nodal metastases compared to histopathology at the time of radical prostatectomy. |
|
|
|
|
|
| HERO Phase 3 Trial: Results Comparing Relugolix, an Oral GnRH Receptor Antagonist, vs. Leuprolide Acetate for Advanced Prostate Cancer |
| Neal Shore, MD, FACS |
| Neal Shore presented the HERO Phase III trial assessing the role of relugolix, an oral GnRH receptor antagonist, compared to leuprolide acetate for advanced prostate cancer at the 2020 AUA virtual experience. |
|
|
|
|
|
| Does Inclusion of MRI in Active Surveillance Decrease The Rate Of Discontinuation? A Reflection Of The Use of MRI in the PRIAS Study |
| Monique Roobol, Ph.D., MSc |
| At the American Urological Association 2020 virtual annual meeting, Monique Roobol and colleagues presented results of their study comparing the rate of active surveillance discontinuation of men included with and without MRI information at inclusion. |
|
|
|
|
|
| Clinical Utility of Preoperative PSMA-targeted 18F-DCFPyL PET/CT in Men with High-risk Prostate Cancer: Diagnostic Performance Comparisons with Pelvic CT or MRI in the OSPREY Prospective, Multi-center Trial |
| Preston C. Sprenkle, MD |
| Preston Sprenkle and colleagues presented initial results of the OSPREY trial, a Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer (OSPREY), assessing the clinical utility of preoperative PSMA-targeted 18F-DCFPyL PET/CT in men with high-risk prostate cancer. |
|
|
|
|
|
 |
|
|
| To view our full coverage of the 2020 AUA Live Virtual Experience, visit the Conference Coverage section on UroToday.com
|
|
|
|
|
|
|
 |
|
|
|
 |
